180 related articles for article (PubMed ID: 34988876)
1. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
DuMond B; Patel V; Gross A; Fung A; Weber S
J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
[TBL] [Abstract][Full Text] [Related]
4. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
6. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
Swain SM; Tan AR; Gianni L; Kuemmel S; Dang CT; Schneeweiss A; O'Shaughnessy J; Liu H; Aguila C; Heeson S; Macharia H; Yang K; Restuccia E; Loibl S
Eur J Cancer; 2023 Jan; 178():70-81. PubMed ID: 36410207
[TBL] [Abstract][Full Text] [Related]
7. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
8. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ; Osgood CL; Gong Y; Zhang H; Bloomquist EW; Jiang X; Qiu J; Yu J; Song P; Rahman NA; Chiu HJ; Ricks TK; Rizvi F; Hou S; Wilson W; Abukhdeir AM; Seidman J; Ghosh S; Philip R; Pierce WF; Bhatnagar V; Kluetz PG; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2021 Apr; 27(8):2126-2129. PubMed ID: 33188141
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.
Sussell JA; Roth JA; Meyer CS; Fung A; Hansen SA
Adv Ther; 2022 Mar; 39(3):1375-1392. PubMed ID: 35094298
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.
Wong CY; Leung R; Kwok GW; Tsang J; Li B; Yau T; Chiu J
Postgrad Med J; 2022 Sep; 98(1163):666-669. PubMed ID: 37062975
[TBL] [Abstract][Full Text] [Related]
15. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
19. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
20. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
